Diplomat Pharmacy will be dispensing a recently approved treatment for rheumatoid arthritis.
Specialty Pharmacy News
“We want to be more impactful to the people we serve and continue to build up our portfolio of products,” Larry Merlo said during the UBS Healthcare Conference in New York City.
According to the agency, this is the first time it has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
“Pharmacists need to understand what’s happening around them regarding the availability of precision medicines and their profiles,” Murray Aitken, executive director of the Quintiles IMS Institute and co-author of the report, said during the International Pharmaceutical Federation 6th Pharmaceutical Sciences World Congress.
Hoffman La Roche’s drug takes aim at the form of vasculitis, a group of disorders that results in inflammation of blood vessels.
The oral therapy is administered twice daily for adults with an FLT3 mutation-positive acute myeloid leukemia diagnosis.
According to the FDA, the expanded approval of Kalydeco triples the number of rare gene mutations that the drug can now treat, expanding the indication from the treatment of 10 mutations, to 33.
During an analyst meeting, the company also said it will share its plans to continue driving sustainable growth by leveraging its strong portfolio of core blockbuster products, the “industry-leading” productivity of its innovation model, and the pending acquisition of Swiss-based biotech company Actelion.
The company’s doxorubicin hydrochloride liposome injection is a sterile, translucent, red liposomal dispersion in 10-mL or 30-mL glass, single-dose vials.
Cliff Osbon talks about how the independent specialty pharmacy differentiates itself from the competition so much that was named to Inc. Magazine’s top growth list five times.